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Open access under the ElsThe aim of the present study was to evaluate the role of HIF-1a genetic polymorphisms and protein
expression in the development of metastasis in upper aerodigestive tract cancer (UADTC) patients. The
expression of pro-angiogenic markers was also evaluated. Protein expression was analysed using immu-
nohistochemistry, and RFLP analysis was used to investigate HIF-1a C1779T and G1790A polymorphisms
in 52 patients with UADTC. Primary lesions were divided into 2 groups according to the absence or pres-
ence of metastasis. Lymph node samples were divided into 3 groups: metastatic lymph nodes, non-met-
astatic lymph nodes (both derived from patients with metastatic disease), and control lymph nodes,
which were obtained from patients without any metastasis. The allele T was more frequently found in
patients with metastatic disease. HIF-1a protein expression in the lymph nodes was increased in the
presence of the T allele. Metastatic lymph nodes showed lower levels of HIF-1a, VEGFR1, and MMP-9 pro-
teins compared to lymph nodes without metastasis, while VEGFR2 protein levels were increased. In
agreement, HIF-1a expression was correlated with MMP-9. Cox regression analysis demonstrated that
higher HIF-1a and MMP-9 protein expression levels and GA and GG genotypes were associated with poor
survival. Our ﬁndings show that the C1772T and G1790A polymorphisms of the HIF-1a gene are associ-
ated with increased expression of the HIF-1a protein in UADTC. The present data indicate that non-met-
astatic tissues express higher levels of HIF-1a, VEGFR1, and MMP-9, while in metastatic lymph nodes,
VEGFR2 protein expression is elevated. The present study also shows that the HIF-1a G1790A polymor-
phism and its protein expression have an impact on the prognosis of UADTC patients.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.Introduction
Upper aerodigestive tract cancer (UADTC) is one of the most
common cancers worldwide.1 The aetiology of UADTC is complex
owing to the multigenic nature of the disease and the number of
potential environmental agents to which affected individuals
may have been exposed. It is clear that the major aetiological
agents are tobacco and alcohol exposure.2 However, other factors
such as genetic predisposition have an important role in disease
genesis and progression.3,4 The role of genetic polymorphisms in
altering protein levels/function and predisposing patients to a vari-
ety of diseases has been demonstrated extensively.5–10Estadual de Montes Claros,
rio de Pesquisa em Saúde,
Gerais, cep 39401-001, Brazil.
.L.S. Guimarães).
evier OA license.Rapid tumour expansion leads to an oxygen demand that
cannot be supported by the existing tumour vasculature. Poorly
oxygenated regions within a tumour are the main characteristics
of the hypoxic phenomenon.11 Hypoxia has not only been associ-
ated with resistance to treatment but also metastasis12 and epithe-
lial–mesenchymal transition.13 The hypoxic response is regulated
by hypoxia-inducible factor-1 (HIF-1), which is a basic helix-
loop-helix transcription factor composed of 2 subunits, HIF-1a
and HIF-1b.14 HIF-1a is the main gene involved in the hypoxic phe-
nomenon, and its polymorphisms have been associated with
metastasis in several solid tumours.15,16 In this context, non-
neoplastic cells can modify speciﬁc sites for future metastatic
adhesion; there is evidence that this cell population can portend
a future metastatic site. This non-neoplastic cell population in-
cludes ﬁbroblasts, haematopoietic progenitors and other cells that
express factors that promote the establishment of metastatic cells.
The identiﬁcation of this cell population in human tissues prior to
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associated with angiogenesis such as vascular endothelial growth
factor A (VEGF-A) and its receptors VEGFR1, VEGFR217, or extracel-
lular matrix degradation proteins such as metallopeptidase-9
(MMP-9).18 Based on these data, the present study aimed to
evaluate the role of HIF-1a genetic polymorphisms and protein
expression in the development of nodal metastases in UADTC
patients. The ﬁndings of previous studies15,19,16,12,20–22 led to the
hypothesis that the HIF-1a C1779T and G1790A polymorphisms
could enhance the HIF-1a pathway by up-regulating HIF-1a pro-
tein expression and facilitate the spread of tumour cells and their
attachment to lymph nodes. Thus, we also evaluated angiogenesis
by assessing the protein expression of VEGF-A, VEGFR1, VEGFR2,
MMP-9, and CD105 at the primary tumour and metastatic and
non-metastatic nodes.
Patients and methods
Patients and ethical aspects
In this retrospective study, we analysed 52 patients who were
diagnosed at a stomatological clinic and referred to the Head and
Neck Service of the Universidade Estadual de Montes Claros (Mon-
tes Claros, Minas Gerais State, Brazil) between 1998 and 2008.23,5
Only cases with available primary tumour and lymph node tissues
for molecular and immunohistochemistry analysis were included
in the study. The health records of these patients were retrieved,
and socio-demographic, clinical, and outcome data were obtained
(Supplementary Table 1). All UADTC patients were classiﬁed on
the basis of the primary site according to the International Union
Against Cancer (UICC)-TNM classiﬁcation of malignant tumours,
as described in the International Classiﬁcation of Diseases for
Oncology.24 One sample from the primary malignant tumour and
at least 1 cervical lymph node were obtained from each UADTC pa-
tient and included in the analysis. Ethical approval for this study
was obtained from the local ethics committees (Unimontes, CEP
1852/2010). All patients underwent surgical resection and were
treated with postoperative radiotherapy.
Evaluation and classiﬁcation of locoregional lymph nodes
All samples were ﬁxed in formalin, embedded in parafﬁn, and
serially sectioned (5-lm thickness). The sections were stained with
haematoxylin and eosin (H&E) and evaluated under a conventional
light microscope. Cervical lymph nodes were analysed using
morphological and immunohistochemical methods to identify a
metastatic focus. A high-molecular weight cytokeratin primary
antibodywasused to identifymicrometastases. Immunohistochem-
istry staining, DNA isolation, and HIF-1a genotyping were per-
formed as described in the Supplementary Materials.
Primary cancer lesion classiﬁcations
Primary lesions were divided into 2 groups according to the
presence (n = 26) or absence of metastasis (n = 26). Patients in
the 2 groups were matched by tumour size, WHO grade, anatomi-
cal site, and age. Other clinical characteristics were also similar
(Supplementary Table 1).
Lymph node classiﬁcations
Histological, immunohistochemical, and clinical examination
revealed lymph node metastases in 26 patients. In this group, the
metastatic and non-metastatic lymph nodes were analysed. In
addition, the lymph nodes from 26 patients without metastasis
were analysed (control group).Statistical analysis
Chi-square and Fisher’s exact statistical tests were used to eval-
uate the association between HIF-1a polymorphic variants and
metastasis. In addition, a multivariate analysis using binary logistic
regression was performed to build a model of variables to evaluate
the risk of locoregional metastasis.
Immunolocalization analysis of HIF-1a, VEGFA, VEGFR1, VEG-
FR2, and MMP-9 proteins assumed non-parametrical distribution,
and comparisons between groups were performed using the
Mann–Whitney test. The analysis of CD105 protein expression in
tissues assumed parametrical distribution, and comparisons be-
tween groups were performed using the Student’s t-test. The
Spearman correlation test was used to evaluate the correlation be-
tween the expression levels of different proteins. For survival anal-
yses, the Kaplan–Meier test was performed, and the variables were
compared using the log-rank test. Variables with p 6 0.25 were in-
cluded in the Cox proportional hazards regression to estimate pre-
dictive factors of crude survival. All statistical analyses were
performed with the statistical software package SPSS, version
13.0 for Windows. P values <0.05 were considered signiﬁcant.
Results
Immunohistochemical and molecular data associated with metastasis
The distribution of HIF-1a genotypes according to the presence
of metastasis is shown in Supplementary Table 2. The data reveal
an association between the C1772T polymorphism and the pres-
ence of metastasis (p = 0.023). The frequency of the CT genotype
was higher in patients that developed metastasis. The allele T
was more frequently found in patients who had metastasis. How-
ever, the G1790A polymorphism was not associated with metasta-
sis (p = 0.172).
To further deﬁne the factors that contribute to metastasis, we
performed binary logistic regression for all lesions and lymph
nodes. In primary lesions, there was no association between the
polymorphism ﬁndings and protein expression levels. The binary
logistic regression showed an association between the CT genotype
and the presence of metastasis (p = 0.009). In addition, low expres-
sion of VEGFR1was correlatedwithmetastasis (p = 0.023) (Table 1).
Genotypes and protein expression in lymph nodes
We next investigated whether the C1772T and G1790A poly-
morphisms could independently induce a change in protein
expression levels. HIF-1a protein expression was higher in the TT
genotype than the CC genotype (79.575 ± 23.293 and
22.625 ± 41.101, respectively; p = 0.027) in all lymph nodes groups.
In metastatic lymph nodes, HIF-1a protein expression in lymph
nodes increased in the presence of the T allele. Similarly, HIF-1a
protein expression was higher in the AA genotype than in the GG
genotype (63.025 ± 47.199 vs. 44.139 ± 41.948; p = 0.028).
Expression of angiogenesis-associated proteins in the different lymph
node groups
Increased expression levels of HIF-1a, VEGFR1, and MMP-9
were observed in non-metastatic lymph nodes (p = 0.047,
p = 0.003, and p = 0.022, respectively). VEGFR2 expression was
higher in tissues from metastatic lymph nodes than in non-
metastatic lymph nodes (Fig. 1). There was no difference in the
expression of any of the proteins studied in non-metastatic lymph
nodes between patients with metastasis and those in the control
group. No difference in neo-vessels (CD105 staining) was observed
between the different lymph node groups.
Table 1
Lymph node parameters associated to risk of locoregional metastasis evaluated by
binary logistic regression in the UADTC patients.
Variables 95 CI
OR Lower Upper p Value
Polymorphism CT
CC Referent
CT 5.481 1.532 19.606 0.009a
TT NA NA NA 0.999
Polymorphism GA
GG Referent
GA 0.679 0.165 2.791 0.592
AA 5.594 0.390 80.268 0.205
Immunohistochemistry
HIF-1 a 0.993 0.980 1.005 0.255
VEGFA 0.989 0.965 1.014 0.394
VEGFR1 0.962 0.930 0.995 0.023a
VEGFR2 1.009 0.985 1.035 0.457
MMP9 0.998 0.970 1.026 0.884
CD105 1.034 0.972 1.100 0.292
OR: odds ratio; CI: conﬁdence interval; n: total number; NA: not applicable. The
model was ﬁtted to the best-ﬁt model.
a Results statistically signiﬁcant.
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lesion
The expression pattern of HIF-1a, VEGF-A, VEGFR1, VEGFR2,
MMP-9, and CD105 in primary lesions analysed by immunohisto-
chemistry is shown in Fig. 2. CD105 was used to identifyFigure 1 Expression of HIF-1a, cytokeratin, VEGF-A, VEGFR1, VEGFR2, MMP-9, and CD10
MMP-9, and CD105 protein expression levels in leukocyte cells of lymph node samples. A
metastatic and non-metastatic groups in the protein expression levels of HIF-1a (a) (p
statistically signiﬁcant differences between metastatic and control groups in the prote
(p = 0.006), and MMP-9 (d) (p = 0.022). There were no statistically signiﬁcant differences
of HIF-1a (B), cytokeratin (C), VEGF-A (D), VEGFR1 (E), VEGFR2 (F), MMP-9 (G), and CD10
and metastatic group (right panel). P values of HIF-1a, VEGF-A, VEGFR1, VEGFR2, and MM
of CD105 protein expression was calculated by Student’s t test. ⁄Counting performed byneo-vessels. The immunohistochemical expression of CD105 in pri-
mary tumours with metastasis was signiﬁcantly higher than in the
group without metastasis (Fig. 2).Protein expression correlations
To understand the effect of HIF-1a on the levels of the other
proteins, we next analysed the correlation between the expression
levels of the different proteins studied in all groups. A positive
correlation was found between HIF-1a and MMP-9 in both the
primary tumour and metastatic samples (r = + 0.374, p = 0.004
and r = + 0.640, p = 0.001, respectively). In the neoplastic cells,
the expression of VEGFA was correlated with VEGFR2 in the
metastatic lymph nodes (r = + 0.418, p = 0.034). The expression of
VEGFR1 was correlated with the expression of MMP-9 in lymph
nodes of patients without metastasis (r = + 0.304, p = 0.029). In all
lymph node groups analysed, the expression of HIF-1a was corre-
lated with the expression of the VEGFR1 protein (r = + 0.232,
p = 0.042). In addition, VEGFR1 was correlated with MMP-9 when
all lymph node groups were analysed (r = + 0.343, p = 0.002).Risk of death and molecular ﬁndings
The mean survival for all patients was 1106.2 days after diagno-
sis. High MMP-9 expression in primary lesions was associated with
poor survival. GG and GA genotypes and elevated HIF-1a protein
expression in lymph nodes had a negative impact on survival
(Table 2).5 proteins in lymph node samples. (A) Analyses of HIF-1a, VEGF-A, VEGFR1, VEGFR2,
nalysis by Mann–Whitney test showed statistically signiﬁcant differences between
= 0.047), VEGFR1 (b) (p = 0.003), and VEGFR2 (c) (p = 0.003). Similarly, there were
in expression levels of HIF-1a (a) (p = 0.029), VEGFR1 (b) (p < 0.001), VEGFR2 (c)
in protein expression levels between non-metastatic and control groups. Expression
5 (H) proteins in the control group (left panel), non-metastatic group (middle panel)
P-9 protein expressions were calculated using the Mann–Whitney test. The P value
microvessel density. Scale bar, 20 lm.
Figure 2 Expression of HIF-1a, VEGF-A, VEGFR1, VEGFR2, MMP-9, and CD105
proteins in primary lesions. (A) Counting was carried out in neoplastic cells of
primary lesions. Note that there was a statistically signiﬁcant increase in the
expression of the CD105 protein in primary lesions that present metastasis (a)
(p < 0.001). The right panel shows the expression levels of HIF-1a (B), VEGF-A (C),
VEGFR1 (D), VEGFR2 (E), MMP-9 (F), and CD105 (G) proteins in primary lesions of
patients with metastasis. The left panel shows the expression of HIF-1a (B), VEGF-A
(C), VEGFR1 (D), VEGFR2 (E), MMP-9 (F), and CD105 (G) proteins in primary lesions
of patients without any metastasis. P values of HIF-1a, VEGF-A, VEGFR1, VEGFR2,
and MMP-9 protein expression levels were calculated using the Mann–Whitney
test. The p value for CD105 protein expression was calculated by Student’s t test.
⁄Counting performed by microvessel density. Scale bar, 50 lm.
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Metastasis is one of the hallmarks of malignant disease and the
cause of death for the majority of cancer patients. The molecular
mechanisms underlying the early onset of metastasis are complex,
involving both genetic and epigenetic alterations in malignant cells
and the tumour environment. Tumour cells have many mecha-
nisms to escape the host defence mechanisms, and metastasis
development requires tumour cells to lose adhesion to surround-
ing cells, cross the basement membrane, migrate through lympha-
tic channels, and subsequently, extravasate into foreign nodal
tissue.25,21 Hypoxia has been shown to promote regional metasta-
sis in several solid tumours.26,27 To maintain cell survival in a
microenvironment that is low in oxygen, cells can alter their pro-
tein expression.28 Under normal oxygen tension, HIF-1a is de-
graded by ubiquitin dependent proteolysis, whereas HIF-1b is
stable.29 Angiogenesis, glycolytic metabolism, and cell survival
and invasion are regulated through HIF-1a signalling.22 During
early tumourigenesis, HIF-1a expression is required for the induc-
tion of angiogenesis although other factors can facilitate tumour
angiogenesis. Liao et al.20 reported that HIF-1a expression acts as
an accelerating factor in tumour progression and metastasis.20
Polymorphisms in the HIF-1a gene have been associated with
an increased risk of developing certain solid tumours.30,15,16
However, the role of single-nucleotide polymorphisms in the
oxygen-dependent degradation domain of the HIF-1a gene in car-
cinogenesis appears complex and is not currently known. To date,
no conclusive results have established a link between HIF-1a poly-
morphism and carcinogenesis.19,18,31–33 Genetic polymorphisms at
C1772T and G1790A of HIF-1a have been associated with in-
creased transcriptional activity16,32 and high expression levels of
HIF-1a in oral cancer.32 Munoz-Guerra et al. demonstrated that
the frequencies of the heterozygous GA and homozygous AA geno-
types were high in patients with oral cancer.34 Our study showed
that the CT heterozygous genotype is associated with lymph node
metastasis. Moreover, based on lymph node analyses, the homozy-
gous TT genotype is associated with a higher number of HIF-1a+
leukocyte cells than the homozygous CC genotype, and HIF-1a+
leukocyte cell numbers are higher in homozygous AA genotypes
than in homozygous GG genotypes.
Although the precise molecular and cellular mechanisms that
control tumour metastasis have not been deﬁned, several studies
have demonstrated that tumours have a predilection for metastasis
to speciﬁc organs. Kaplan et al.17 introduced the concept that tu-
mour metastasis is initiated by a well-deﬁned sequence of events
that depend on the expression patterns of ﬁbronectin and VEG-
FR1+VLA4+ clusters, which dictate organ-speciﬁc tumour spread.
These clusters can modify the microenvironment by regulating
the production of MMP-9, resulting in the attraction of tumour
cells and their establishment in a niche.17 HIF-1a might enhance
this signalling by up-regulating MMP-918 and VEGFR1 expression
in these sites. In the present study, increased expression of HIF-
1a, VEGFR1, and MMP-9 was detected in non-metastatic lymph
nodes compared to metastatic samples. In addition, VEGFR1 pro-
tein expression was correlated with HIF-1a and MMP-9 protein
levels in non-metastatic lymph nodes. According to the pre-meta-
static niche theory, non-metastatic lymph nodes prepare for tu-
mour cell spreading by up-regulating some proteins. After the
establishment of the metastases, a down-regulation of the proteins
is observed.17,35 Notably, a decrease in protein levels after metasta-
sis does not occur in some types of tumours.36 Therefore, distinct
time-dependent events may or may not occur before, during, and
after the establishment of a metastatic niche.
Despite contradictory results on the clinical signiﬁcance of
microvessel density in UADTC, this parameter has been regarded
Table 2
Cox regression analyses in the UADTC patients with a follow-up of 3554 days taken
primary lesions and all lymph nodes from this study.
Variables 95 CI
OR Lower Upper p Value
Polymorphism CT
CC Referent
CT 1.708 0.586 4.978 0.327
TT NA NA NA 0.982
Polymorphism GA
AA Referent
GG 27.651 2.151 355.519 0.011a
GA 37.898 3.497 410.702 0.003a
Immunohistochemistry – Primary lesions
HIF-1 a 0.985 0.970 1.000 0.053
VEGFA 0.988 0.976 1.000 0.052
VEGFR1 0.996 0.984 1.009 0.546
VEGFR2 1.001 0.988 1.014 0.857
MMP9 1.016 1.004 1.029 0.007a
CD105 1.011 0.935 1.094 0.781
Immunohistochemistry – Lymph nodes
HIF-1 a 1.013 1.003 1.023 0.014a
VEGFA 0.994 0.965 1.023 0.673
VEGFR1 0.976 0.948 1.004 0.089
VEGFR2 1.004 0.990 1.017 0.585
MMP9 0.993 0.971 1.016 0.554
CD105 0.967 0.924 1.013 0.159
OR: odds ratio; CI: conﬁdence interval; n: total number; NA: not applicable. The
model was ﬁtted to the best-ﬁt model.
a Results statistically signiﬁcant.
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may be due to differences in treatment protocols and the endothe-
lial markers used for immunohistochemical staining. CD105 binds
preferentially to activate endothelial cells undergoing angiogene-
sis, and it has been found to be a better marker for evaluating
ongoing tumour angiogenesis than other pan-endothelial mark-
ers.37 Our data show that higher expression levels of CD105 are sig-
niﬁcantly associated with lymph node metastases, which implies
that increasing the number of vessels in a tumour provides an
environment in which the tumour is susceptible to being dissemi-
nated. The molecular basis for CD105 up-regulation is not clear,
but the CD105 gene promoter has been shown to be predominantly
active in proliferating endothelial cells undergoing hypoxia via the
HIF-1 complex, which binds a functional consensus hypoxia
response element (HRE) in the CD105 promoter.38 In our study,Figure 3 Proposed model of HIF-1a, MMP-9, VEGFR1, and VEGFR2 + leukocyte cells in
MMP-9, and VEGFR1 proteins are up-regulated in pre-metastatic lymph nodes. These ce
support the establishment of metastases. Recruitment of VEGFR2 + leukocyte cells to the
colonization of macrometastases.HIF-1a showed higher expression levels in non-metastatic lymph
nodes than in metastatic lymph nodes. The distribution and
expression of CD105 in UADTC samples was not consistent with
that of HIF-1a in lymph node samples. These ﬁndings provide com-
pelling evidence that CD105, but not HIF-1a, is required for angio-
genesis in lymph nodes after metastatic spread. These results are
supported by the correlation between VEGFR2, the main trans-
ducer of VEGFA-mediated angiogenic signals, VEGFA protein
expression in metastatic tissues, and by the higher expression of
VEGFR2 in metastatic compared with non-metastatic lymph nodes.
Consistent with an increase in tumour cell dissemination, VEGFR2
stimulates neovascularization of the tumour after the arrival of
VEGFR1+ cells and metastasis spread. Furthermore, VEGFR2+ cells
are essential for the growth and progression of malignant cells in
the new organ.17
In the present study, we focused on metastatic and non-meta-
static lymph nodes from UADTC patients. As head and neck cancers
refer to a group of biologically similar cancers that may affect
different regions, including the oral cavity, nasal cavity, paranasal
sinus, pharynx, and larynx, we restricted our selection criteria to
tumours located in the oral cavity, pharynx, and larynx. Although
there are no reports of HIF-1a levels in metastatic and non-
metastatic lymph nodes from UADTC patients, some studies have
compared HIF-1a expression in primary lesions and metastatic
lymph nodes. Shim et al. demonstrated that the expression of
HIF-1a was higher in metastatic lymph nodes than in primary le-
sions. We did not ﬁnd any differences in HIF-1a protein expression
between primary lesions and metastatic sites (data not shown).
However, patients with metastatic disease and a homozygous TT
genotype showed higher HIF-1a protein expression. A previous
study demonstrated that bone metastasis from human breast car-
cinoma can modify the microenvironmental signals controlled by
COX-2 induction and HIF-1a activation. In agreement with these
ﬁndings, HIF-1a+ bone marrow supportive cells were detected in
metastasis-bearing animals.39 We observed the highest HIF-1a
protein expression in non-metastatic samples. These results, in
conjunction with previous studies,40 suggest that HIF-1a has an
important role in the initial stages of metastasis or in a more hyp-
oxic environment in non-metastatic lymph nodes. Taken together,
our results suggest that HIF-1a polymorphisms can alter HIF-1a
protein expression and simultaneously enhance VEGFR1 and
MMP-9 protein signals in a non-metastatic niche, thereby altering
the microenvironment and supporting metastasis at that site, with
the consequent negative impact on survival. A proposed model ofUADTC metastasis. In response to factors secreted by the primary tumour, HIF-1a,
lls secrete a variety of pre-metastatic factors that alter the microenvironment and
early metastatic niche mediates the angiogenic switch and enables progression and
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metastasis is shown in Fig. 3.Conclusion
In conclusion, our study demonstrated that the C1772T and
G1790A polymorphisms of the HIF-1a gene are associated with in-
creased expression of the HIF-1a protein in UADTC. Our data indi-
cate that the expressions of HIF-1a, VEGFR1, and MMP-9 increase
in non-metastatic tissues, while the VEGFR2 protein is expressed at
higher levels in metastatic lymph nodes. Finally, the present study
shows that the HIF-1a G1790A polymorphism and its protein
expression have an impact on the prognosis of patients with
UADTC. These ﬁndings suggest an additional role for HIF-1a in
UADTC. Further studies are necessary to elucidate the HIF-1a path-
way, which would facilitate the development of novel therapeutic
strategies for the prevention and treatment of metastases in
UADTC and other solid tumours.Acknowledgements
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